PolyPid Ltd.

NasdaqCM:PYPD Stock Report

Market Cap: US$22.8m

PolyPid Management

Management criteria checks 3/4

PolyPid's CEO is Dikla Czaczkes Akselbrad, appointed in Jul 2022, has a tenure of 1.75 years. total yearly compensation is $557.44K, comprised of 62.4% salary and 37.6% bonuses, including company stock and options. directly owns 0.01% of the company’s shares, worth $2.22K. The average tenure of the management team and the board of directors is 2 years and 3.9 years respectively.

Key information

Dikla Czaczkes Akselbrad

Chief executive officer

US$557.4k

Total compensation

CEO salary percentage62.4%
CEO tenure1.8yrs
CEO ownership0.01%
Management average tenure2yrs
Board average tenure3.9yrs

Recent management updates

Recent updates

PolyPid set to cut 20% jobs

Oct 20

PolyPid's surgical site infections treatment eligible for marketing nod submission in EU

Sep 28

PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections

Sep 02

PolyPid GAAP EPS of -$1.23 misses by $0.60

Aug 10

PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe

Aug 03

PolyPid: Strong Pipeline, Close Catalysts

Apr 19

Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?

Mar 18
Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?

Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation

Nov 08
Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation

We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth

Jul 15
We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation

Mar 09
Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation

PolyPid's oncoplex cancer program shows encouraging action in animal study

Dec 22

PolyPid launches second late-stage trial with D-PLEX100 in surgical infections

Dec 16

PolyPid pops 24% after D-PLEX100 nabs accelerated review in U.S. for preventing surgical infections

Nov 24

CEO Compensation Analysis

How has Dikla Czaczkes Akselbrad's remuneration changed compared to PolyPid's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$557kUS$348k

-US$24m

Sep 30 2023n/an/a

-US$24m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$34m

Dec 31 2022US$749kUS$356k

-US$40m

Sep 30 2022n/an/a

-US$46m

Jun 30 2022n/an/a

-US$47m

Mar 31 2022n/an/a

-US$46m

Dec 31 2021US$848kUS$382k

-US$43m

Sep 30 2021n/an/a

-US$41m

Jun 30 2021n/an/a

-US$37m

Mar 31 2021n/an/a

-US$46m

Dec 31 2020US$1mUS$261k

-US$43m

Compensation vs Market: Dikla's total compensation ($USD557.44K) is about average for companies of similar size in the US market ($USD670.12K).

Compensation vs Earnings: Dikla's compensation has been consistent with company performance over the past year.

CEO

Dikla Czaczkes Akselbrad (50 yo)

1.8yrs

Tenure

US$557,441

Compensation

Ms. Dikla Czaczkes Akselbrad was an Executive Vice President and Chief Financial Officer of PolyPid Ltd. since December 2016 until July 1, 2022 and serves as its Chief Executive Officer since July 1, 2022...

Leadership Team

NamePositionTenureCompensationOwnership
Dikla Czaczkes Akselbrad
CEO & Director1.8yrsUS$557.44k0.0097%
$ 2.2k
Jonny Missulawin
Chief Financial Officer1.7yrsUS$379.57kno data
Dalit Hazan
Executive Vice President of R&D and Clinical & Regulatory Affairs2.8yrsUS$598.18kno data
Ori Warshavsky
Chief Operating Officer - USno dataUS$512.92k0.0056%
$ 1.3k
Maria Rubin
Vice President of Operationsless than a yearno datano data
Tal Vilnai
General Counsel & Corporate Secretary2.3yrsno datano data
Rivi Lev-ari
Vice President of Human Resourceno datano datano data
Jean-Marc Hagai
Chief Commercial Officer2.2yrsno datano data

2.0yrs

Average Tenure

47.5yo

Average Age

Experienced Management: PYPD's management team is not considered experienced ( 2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Dikla Czaczkes Akselbrad
CEO & Director1.7yrsUS$557.44k0.0097%
$ 2.2k
Robert Stein
Independent Director3.8yrsno datano data
Itzhak Krinsky
Independent Director5.3yrsno data0.017%
$ 4.0k
Yafit Stark
Clinical Development Strategy Advisorno datano datano data
Yechezkel Barenholz
Independent Director16yrsno data0.058%
$ 13.1k
Nir Dror
Independent Director3.9yrsno datano data
Jacob Harel
Independent Chairman6.4yrsno data0.0097%
$ 2.2k
Moshe Salai
Member of Scientific Advisory Boardno datano datano data
Erez Kachel
Member of Scientific Advisory Boardno datano datano data
Hartzell Schaff
Member of Scientific Advisory Board7.3yrsno datano data
Frederick Lang
Member of Scientific Advisory Board2.4yrsno datano data
Mitchel Berger
Member of Scientific Advisory Board2.3yrsno datano data

3.9yrs

Average Tenure

68yo

Average Age

Experienced Board: PYPD's board of directors are considered experienced (3.9 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.